2.2500 0.00 (0.00%)
After hours: 5:16PM EDT
|Bid||2.2100 x 3200|
|Ask||2.2500 x 3100|
|Day's Range||2.2300 - 2.3965|
|52 Week Range||1.9200 - 5.6800|
|Beta (3Y Monthly)||2.62|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Inovio (INO) stops the development of INO-5401 for advanced bladder cancer, and cuts workforce by 28% and annual burn rate by 25% as part of the restructuring process.
Inovio (INO) closes enrollment in the phase II study evaluating VGX-3100 for the treatment of HPV-related high-grade anal dysplasia. Shares up.
Inovio (INO) delivered earnings and revenue surprises of -7.14% and -97.10%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Inovio (INO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Inovio (INO) stops the phase I/II study on INO-5401 for advanced bladder cancer and cuts its workforce by 28% and annual burn rate by 25%. Shares fall in after-hours trading.
In 2009 J. Kim was appointed CEO of Inovio Pharmaceuticals, Inc. (NASDAQ:INO). This analysis aims first to contrast...
Inovio (INO) concludes enrollment in the phase III study (REVEAL 1), which currently evaluates VGX-3100 for the treatment of cervical dysplasia, caused by HPV. Shares rally.
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) is a small-cap stock with a market capitalization of US$240m. While...
CEO of Inovio Pharmaceuticals Inc (NASDAQ:INO) Jong Joseph Kim sold 2,129,553 shares of INO on 06/03/2019 at an average price of $2.36 a share.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 28) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Arrowhead ...